Most previous studies have either focused on GLP-1 receptor-specific agonists and polyagonists for weight management in individuals with obesity or overweight without diabetes, or, as in the case of the recent meta-analysis by Yao et al. (2024), has evaluated GLP-1 receptor agonists for T2DM in a broader sense. This evidence concerns the gene GLP1R and diabetes mellitus.